Chiesi Group Company Profile

12:22 EDT 6th October 2015 | BioPortfolio

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,700 employees, of whom 300 are involved in research and development activities.

Chiesi’s technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures.

Chiesi's formula for success is based on a peculiar approach that allows to combine factors often thought of as opposites in the pharmaceutical industry – such as research and ethics, technology and humanity, commitment to results and concern for individuals, reliability and empathy – while encouraging innovation at all levels. The final goal is the creation of value through innovation.


Chiesi Farmaceutici S.p.A.Via Palermo, 26/A,


Phone: 39 0521 2791
Fax: 39 0521 774468

News Articles [179 Associated News Articles listed on BioPortfolio]

Chiesi unveils new Manchester, UK headquarters

Italian family owned pharma company Chiesi has unveiled its new headquarters at Manchester Green, near…

Chiesi rapped for ABPI code breach

Chiesi made its sales reps go through a ‘tick-box’ compliance training exercise to get the pharma industry regulator ‘off its back’ – according to a public reprimand by the industry standard...

uniQure, Chiesi sales and marketing update

Holoclar® - The first stem-cell therapy approved for medical use in Europe

Dr Andreas Chiesi, CEO, Holostem Terapie Avanzate S.r.l

July 2015: AWMSG approvals

The following medicines have been approved for use in NHS Wales by the All Wales Medicines Strategy Group (AWMSG): Fostair (beclometasone/formoterol; Chiesi) inhaler for patients with chronic obstruct...

Further delays for Ventmax

Further supply issues for Ventmax (salbutamol sulphate; Chiesi) SR capsules 4mg and 8mg mean that the products will not be back in stock before September 2015.

Chiesi Farmaceutici SpA - Product Pipeline Review - 2015

Recently added to the BioPortfolio report store, Chiesi Farmaceutici SpA - Product Pipeline Review - 2015 is a new report from Global Markets Direct published on 2015-05-19. This 56-page report is av...

Hyperglycaemia with Peyona

Hyperglycaemia has been added as a common adverse event in the summary of product characteristics for Peyona (caffeine citrate; Chiesi).

PubMed Articles [2343 Associated PubMed Articles listed on BioPortfolio]

Enzymatic Debridement in Necrotizing Pancreatitis.

Multiple organ failure and pancreatic necrosis are the factors that determine prognosis in acute pancreatitis attacks. We investigated the effects of collagenase on the debridement of experimental pan...

When talking makes you feel like a group: The emergence of group-based emotions.

Group-based emotions are emotional reactions to group concerns and have been shown to emerge when people appraise events while endorsing a specific social identity. Here we investigate whether discuss...

Commentary on "Toward Understanding and Treating Violence in America: Some Contributions From Group Dynamic and Group Therapy Perspectives".

Commentary on "Toward Understanding and Treating Violence in America: Some Contributions From Group Dynamic and Group Therapy Perspectives".

Degenerative changes in the interspinous ligament.

Objective: The aim of this study was to investigate the imaging assessment of interspinous ligament degeneration (ISLD) in patients with or without low back pain (LBP). Methods: Sixty patients with LB...

Clinical Trials [1806 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Does Cognitive Rehabilitation Demonstrate Benefits in the Group Setting With People Whom Have Experienced Brain Injury?

The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...

Short Term Group Therapy for OCD

Assessing OCD before and after group therapy

Early Group Based Parental Support Within Child Health Service - Group Leadership

All parents in Sweden are offered group based parental support within Child Health Service (CHS) but only 40% participate. Nurses feel insecure in their group leadership and express a need...

Sublingual Microcirculation Data of Patients With Systemic Diseases

This is an observational clinical study, patients with systemic diseases will be enrolled according to the inclusion and exclusion criteria. 360 patients will received the examination of s...

Companies [1494 Associated Companies listed on BioPortfolio]

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

ACE Group

Celebrating 25 years of insuring progress, the ACE Group is a global leader in insurance and reinsurance serving a diverse group of clients. Headed by ACE Limited (NYSE:ACE), a co...

More Information about "Chiesi Group" on BioPortfolio

We have published hundreds of Chiesi Group news stories on BioPortfolio along with dozens of Chiesi Group Clinical Trials and PubMed Articles about Chiesi Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Group Companies in our database. You can also find out about relevant Chiesi Group Drugs and Medications on this site too.


Relevant Topic

Latest News Clinical Trials Research Drugs Reports Corporate
Bioethics is the study of controversial ethics brought about by advances in biology and medicine. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philo...

Corporate Database Quicklinks

Searches Linking to this Company Record